{
    "clinical_study": {
        "@rank": "142811", 
        "arm_group": {
            "arm_group_label": "Supportive care (palliative care support)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies supportive care for patients with hematological\n      malignancies undergoing hematopoietic cell transplant. Supportive care may improve quality\n      of life in this patient population."
        }, 
        "brief_title": "Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant", 
        "condition": "Hematopoietic/Lymphoid Cancer", 
        "condition_browse": {
            "mesh_term": "Hematologic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Pilot a supportive care intervention that begins prior to transplantation and continues\n      through the acute peritransplant period.\n\n      II. Determine the proportion of patients who enroll and the level of comfort / distress of\n      hematopoietic cell transplant (HCT) patients who meet with the supportive care team.\n\n      III. Pilot data collection mechanisms and cost retrieval in preparation for a randomized\n      clinical trial.\n\n      OUTLINE:\n\n      Patients undergo supportive care consultation before transplantation and at least once\n      monthly while they remain at the transplant center."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  English as primary language\n\n          -  Planned autologous or allogeneic hematopoietic cell transplantation\n\n          -  Presence of co-morbidities (hematopoietic cell transplant co-morbidity index [HCT-CI]\n             score 3 or greater), high risk disease (relapse risk > 25%), or a planned type of\n             transplant (human leukocyte antigen [HLA]-mismatched allogeneic or myeloablative)\n             that places the patient at a higher than average risk of non-relapse mortality or\n             relapse\n\n        Exclusion Criteria:\n\n          -  Major psychiatric diagnosis that impairs cognitive functioning or is not controlled\n             at the time of the approach, as judged by the patient's medical team\n\n          -  First transplant of a planned tandem procedure (the second transplant is eligible)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758484", 
            "org_study_id": "2659.00", 
            "secondary_id": [
                "NCI-2012-03009", 
                "P30CA015704"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Supportive care (palliative care support)", 
                "description": "Undergo supportive care intervention", 
                "intervention_name": "palliative care", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Supportive care (palliative care support)", 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Supportive care (palliative care support)", 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "quality of life assessment"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hematopoietic cell transplantation", 
            "Supportive/palliative care"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "last_name": "Rebecca S. Clark", 
                "phone": "206-667-4160"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
            }, 
            "investigator": {
                "last_name": "Stephanie J. Lee", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "FEASIBILITY OF IMPLEMENTING PRE-TRANSPLANT EVALUATION BY THE SUPPORTIVE CARE TEAM FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Stephanie Lee", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Will mainly be descriptive.", 
                "measure": "Study participation rates defined as the proportion of patients who consent to enroll", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 months"
            }, 
            {
                "description": "Will mainly be descriptive.", 
                "measure": "Completion time for the supportive care consultation", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days post-treatment"
            }, 
            {
                "description": "Will mainly be descriptive. The post-consultation scores measuring level of comfort or distress per topic in the supportive care consultation will be summarized per item.", 
                "measure": "Level of comfort / distress attributed to individual parts of the consultation", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days post-treatment"
            }, 
            {
                "description": "Will mainly be descriptive. The completeness of follow-up data collection will be calculated and reported as a proportion of successfully completed scales vs. scales attempted to be collected or completed by patients.", 
                "measure": "Completeness of follow-up data collection, where completeness is defined by the proportion of instrument scores that can be calculated per given time point", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days post-treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758484"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}